STE
HealthcareSteris
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2017–2025(9yr)| Metric | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.8B | $3.0B | $3.1B | $4.6B | $5.0B | $5.1B | $5.5B | +6.2% |
| Gross Profit | $1.0B | $1.1B | $1.2B | $1.3B | $1.3B | $2.0B | $2.2B | $2.2B | $2.4B | +8.3% |
| Gross Margin | 39.3% | 41.7% | 42.2% | 43.5% | 43.2% | 44.0% | 43.6% | 43.2% | 44.0% | +0.8pp |
| Operating Income | $226.2M | $399.9M | $411.5M | $537.0M | $548.4M | $425.6M | $268.2M | $836.1M | $866.6M | +3.7% |
| Operating Margin | 8.7% | 15.3% | 14.8% | 17.7% | 17.6% | 9.3% | 5.4% | 16.3% | 15.9% | -0.4pp |
| Net Income | $110.0M | $290.9M | $304.1M | $407.6M | $397.4M | $243.9M | $107.0M | $378.2M | $614.6M | +62.5% |
| Net Margin | 4.2% | 11.1% | 10.9% | 13.4% | 12.8% | 5.3% | 2.2% | 7.4% | 11.3% | +3.9pp |
| Free Cash Flow | $251.2M | $292.2M | $349.8M | $376.0M | $450.4M | $397.2M | $395.0M | $612.9M | $778.0M | +26.9% |
| FCF Margin | 9.6% | 11.2% | 12.6% | 12.4% | 14.5% | 8.7% | 8.0% | 11.9% | 14.3% | +2.3pp |
| EPS (Diluted) | $1.28 | $3.39 | $3.56 | $4.76 | $4.63 | $2.48 | $1.07 | $3.81 | $6.20 | +62.7% |
1. THE BIG PICTURE
Steris is an essential infrastructure provider for the global healthcare system, but its reliance on specific chemical sterilization methods has turned a core operational strength into a significant legal and regulatory liability. While Steris is delivering high-single-digit growth and industry-leading operating margins, it must navigate a $2 billion debt load and a shifting regulatory landscape that threatens its primary service facilities.
2. WHERE THE RISKS HIT HARDEST
The "global network of contract sterilization facilities" that Steris cites as a key differentiator (10-K Item 1) is directly threatened by ethylene oxide (EO) regulatory exposure. Because EO is a core modality for these 60+ facilities, new emissions regulations or further litigation—following the $48.2 million settlement in March 2025—could force facility closures or significantly raise operating costs (Risks). Furthermore, Steris’s "technology-neutral offering" is undermined by supply chain concentration; Steris relies on single-sourced materials like cobalt-60 and EO, making its most profitable segment vulnerable to localized disruptions or price spikes (10-K Item 1). Finally, the strategic goal of providing "superior returns for Shareholders" (10-K Item 1) is constrained by $2,043.7 million in total debt, which consumes cash flow for interest payments and limits the capital available for the acquisitions that have historically built its $4 billion in goodwill (Risks).
3. WHAT THE NUMBERS SAY TOGETHER
Steris maintains the highest operating margin in its peer group at 18.0%, suggesting that its "Minimum Standard of Lean" (MSoL) framework is successfully driving efficiency in a business dominated by physical equipment and services (Peer Benchmarking). This operational discipline is translating into a 17.0% free cash flow margin, which ranks third among its peers and comfortably supports its 1.2% buyback yield.
Recent results show a growth acceleration: the 9.2% revenue increase in the third quarter of fiscal 2026 (10-Q) is notably higher than the trailing twelve-month growth of 6.2% (Peer Benchmarking). This uptick is broad-based, with the Healthcare segment growing 9% and Applied Sterilization Technologies (AST) rising 11% (8-K). Management is achieving these gains despite a projected $55 million pre-tax profit reduction due to tariffs, indicating that pricing power and service volume are currently strong enough to offset macroeconomic headwinds (8-K).
4. IS IT WORTH IT AT THIS PRICE?
At 20.1x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Steris trades at a 36% premium to the peer median of 14.8x (Peer Benchmarking). According to (CAPM analysis), the market is pricing in approximately 5.2% long-term growth. This valuation appears justified by current fundamentals, as Steris’s projected fiscal 2026 revenue growth of 8-9% and its recent 9.2% quarterly growth both exceed the market’s implied requirement.
However, this premium leaves little room for error regarding the $6 billion in goodwill and intangible assets on the balance sheet. If growth slows to 2.5%, the justified multiple would drop to 13.0x (CAPM analysis). The primary factor that could trigger such a re-rating is the EO litigation; if legal costs escalate or regulatory changes force a shift away from current sterilization modalities, Steris's superior 18% operating margin could compress toward the peer average.
5. WHAT WOULD CHANGE THIS VIEW?
- Cautious if Steris reports an impairment charge on its $4 billion in goodwill, which would signal that its recent acquisitions are failing to generate the expected returns in a high-interest-rate environment (Risks).
- Constructive if the AST segment’s capital equipment revenue—which surged 103% in the most recent quarter—maintains its momentum, suggesting a long-term cycle of customers upgrading to Steris’s proprietary control systems (8-K).
- Cautious if the $2,043.7 million debt load increases, as higher leverage would further limit the financial flexibility needed to settle ongoing EO litigation (Risks).
6. BOTTOM LINE
Structural Advantage: High customer switching costs and industry-leading operating efficiency derived from a global network of specialized sterilization facilities and the proprietary MSoL lean framework.
Bottom Line: Steris is a top-tier operator with a clear valuation premium, but the investment case depends entirely on management's ability to outrun the mounting legal and regulatory costs of its core sterilization technology.
1. Top 5 Material Risks
- Ethylene Oxide (EO) Regulatory and Legal Exposure: Steris operates a network of over 60 contract sterilization facilities, with EO sterilization being a core modality. Regulatory actions or litigation regarding EO emissions—such as the $48.2 million settlement agreed to in March 2025—could significantly increase operating costs, force facility closures, or lead to a shortage of medical devices, thereby reducing demand for Steris’s Healthcare products.
- Debt Obligations: As of March 31, 2025, Steris held approximately $2,043.7 million in total indebtedness. This leverage restricts Steris’s ability to obtain additional financing, requires significant cash flow for principal and interest payments, and creates a competitive disadvantage compared to less-indebted peers.
- Goodwill and Intangible Asset Impairment: Steris’s balance sheet includes $4 billion in goodwill and $2 billion in net intangible assets. If these assets are determined to be impaired during annual or interim evaluations, Steris would be required to recognize an impairment loss, resulting in a material non-cash charge to its financial results.
- Geopolitical and Macroeconomic Instability: Ongoing instability, including supply chain disruptions, inflation, and rising interest rates, threatens Steris’s production costs and customer demand. Specifically, changes in international trade policy and tariffs could increase production costs and limit access to end markets, potentially necessitating material changes to the global production footprint.
- Healthcare Policy and Reimbursement: A significant portion of Steris’s revenue is derived from customers reliant on government healthcare funding or third-party reimbursement. Changes in these systems, or public budgetary constraints, may lead to decreased healthcare utilization and pricing pressure on Steris’s capital products and services.
2. Company-Specific Risks
- Integration of Acquisitions: Steris has completed several large acquisitions and expects to incur substantial non-recurring costs related to integrating these businesses, including employee retention, severance, and facility consolidation expenses. Failure to realize anticipated synergies or cost savings could negatively impact financial performance.
- Lean Business Initiatives: Steris’s strategy to incorporate Lean concepts and in-source production is complex and time-consuming. If these initiatives fail to produce expected efficiencies or if initial costs exceed projections, profitability may be negatively impacted.
- Cybersecurity Vulnerabilities: Steris relies on extensive IT systems and third-party providers for order fulfillment, invoicing, and data hosting. A successful cyberattack or failure of these systems could lead to reputational harm, litigation, and regulatory action, including potential fines under the GDPR of up to 4% of global annual revenues.
- Corporate Responsibility Expectations: Failure to meet evolving stakeholder expectations regarding sustainability and greenhouse gas emissions reporting—such as the requirements under the Corporate Sustainability Reporting Directive (CSRD)—could lead to reputational damage, advocacy group campaigns, or litigation.
3. Regulatory/Legal Risks
- Anti-Bribery Compliance: Steris is subject to the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act. Despite internal policies, Steris cannot guarantee that its employees or agents will not violate these laws, which could result in significant sanctions.
- Tax Residency and Legislation: The IRS may assert that Steris should be treated as a U.S. corporation for tax purposes under Section 7874 of the Code, which would subject Steris to substantial additional U.S. tax liability. Additionally, the implementation of the OECD’s Global Base Erosion (GloBE) rules could increase Steris’s effective tax rate in jurisdictions where the rate is below 15%.
- Product Liability: Steris faces inherent risks of product liability claims. If the number or severity of these claims increases, Steris may incur substantial costs that exceed insurance coverage limits, particularly if insurers deny coverage or become insolvent.
4. Financial Impact Map
- EO Litigation and Regulatory Compliance → Results of Operations → Costs associated with legal settlements, facility modifications, and potential loss of revenue from EO sterilization services.
- Total Indebtedness ($2,043.7 million) → Cash Flow from Operations → Reduction in available cash for dividends, stock repurchases, and capital expenditures due to principal and interest payments.
- Goodwill ($4 billion) and Intangible Assets ($2 billion) → Results of Operations → Potential material non-cash impairment charges if carrying amounts exceed fair value.
- Tariffs and Trade Policy Changes → Products Gross Margin → Increased production costs and potential asset impairment charges resulting from changes to the global production footprint.
- GDPR Non-Compliance → Results of Operations → Potential financial penalties of up to 4% of global annual revenues for the preceding financial year.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-Q | Feb 2026 | Dec 2025 |
| 8-K | Feb 2026 | — |
| 14A | Jun 2025 | — |
| 10-K | May 2025 | Mar 2025 |